venBio Partners LLC Buys New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

venBio Partners LLC bought a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 7,102,190 shares of the company's stock, valued at approximately $4,545,000. Lyell Immunopharma makes up 2.7% of venBio Partners LLC's investment portfolio, making the stock its 7th biggest position. venBio Partners LLC owned approximately 2.43% of Lyell Immunopharma as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of LYEL. Graham Capital Management L.P. acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $33,000. RPO LLC acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $42,000. Wells Fargo & Company MN raised its stake in shares of Lyell Immunopharma by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock valued at $60,000 after purchasing an additional 20,542 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Lyell Immunopharma by 102.8% in the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after purchasing an additional 59,182 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $162,000. Institutional investors and hedge funds own 66.05% of the company's stock.

Insider Buying and Selling

In other news, CEO Lynn Seely bought 175,000 shares of the firm's stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the transaction, the chief executive officer now owns 712,500 shares in the company, valued at approximately $434,625. This trade represents a 32.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Charles W. Newton bought 200,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $0.56 per share, with a total value of $112,000.00. Following the transaction, the chief financial officer now owns 200,000 shares in the company, valued at $112,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 768,640 shares of company stock worth $449,508 over the last quarter. 25.10% of the stock is owned by company insiders.

Lyell Immunopharma Trading Down 1.0%

LYEL traded down $0.00 on Friday, hitting $0.42. 527,077 shares of the company's stock were exchanged, compared to its average volume of 1,036,056. The firm has a market cap of $123.48 million, a PE ratio of -0.53 and a beta of -0.25. Lyell Immunopharma, Inc. has a twelve month low of $0.39 and a twelve month high of $2.85. The stock has a fifty day moving average of $0.46 and a two-hundred day moving average of $0.63.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "neutral" rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Wednesday, April 16th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.